Evidence map›Paper›PMID 27471869›Full record

Trial reportBlood cancer journal2016

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, S Thanendrarajan, J Sawyer, D Alapat, E Tian, C Stein and 14 more

Erratum issuedAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Y JethavaMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
A MitchellCancer Research and Biostatistics, Seattle, WA, USA.
M ZangariMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
S WaheedMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
C SchinkeMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
S ThanendrarajanMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
J SawyerMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
D AlapatMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
E TianMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
C SteinMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
R KhanMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
C J HeuckMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
N PettyMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
D AveryMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
D StewardMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
R SmithMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
C BaileyMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
J EpsteinMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
S YaccobyMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
A HoeringCancer Research and Biostatistics, Seattle, WA, USA.
J CrowleyCancer Research and Biostatistics, Seattle, WA, USA.
G MorganMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
B BarlogieMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
F van RheeMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Funding

Tumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BELLAMY, WILLIAM T · 1993 to 2013
$49.7M
NCI NIH HHS P01 CA055819
6 · The paper itself

Abstract

Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used and we reported that gene expression profile (GEP)-defined high risk was a major predictor of relapse. In spite of our best efforts, the majority of GEP70 high-risk patients relapse and we have noted higher relapse rates during drug-free intervals. This prompted us to explore the concept of less intense drug dosing with shorter intervals between courses with the aim of preventing inter-course relapse. Here we report the outcome of the Total Therapy 5 trial, where this concept was tested. This regimen effectively reduced early mortality and relapse but failed to improve progression-free survival and overall survival due to relapse early during maintenance.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDisease-Free SurvivalDose-Response Relationship, DrugFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLenalidomideMaleMelphalanMiddle AgedMultiple MyelomaNeoplasm ProteinsBortezomibLenalidomideMelphalanNeoplasm ProteinsThalidomide

Identifiers

PMID27471869
PMCPMC5030385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.